Table 1 Baseline demographic and clinical characteristics of patients before and after matching
Characteristic | Pre-match | P value | Post-match1 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Patients treated with | Patients treated with | |||||||||
Exenatide BID | Insulin glargine | Exenatide BID | Insulin glargine | |||||||
N = 9,197 | N = 4,499 | N = 3,774 | N = 3,774 | |||||||
N/Mean | %/SD | N/Mean | %/SD | N/Mean | %/SD | N/Mean | %/SD | Std. diff. | ||
Age: mean (years) | 54 | 10 | 59 | 12 | < 0.0001 | 57 | 10 | 57 | 12 | 7.8 |
Age: group | < 0.0001 | |||||||||
18-34 | 267 | 2.9% | 72 | 1.6% | 71 | 1.9% | 66 | 1.7% | 1.0 | |
35-44 | 1,183 | 12.9% | 397 | 8.8% | 368 | 9.8% | 381 | 10.1% | 1.2 | |
45-54 | 3,135 | 34.1% | 1,146 | 25.5% | 1,077 | 28.5% | 1,073 | 28.4% | 0.2 | |
55-64 | 3,307 | 36.0% | 1,382 | 30.7% | 1,289 | 34.2% | 1,272 | 33.7% | 1.0 | |
65+ | 1,305 | 14.2% | 1,502 | 33.4% | 969 | 25.7% | 982 | 26.0% | 0.8 | |
Sex: female | 5,359 | 58.3% | 1,948 | 43.3% | < 0.0001 | 1,720 | 45.6% | 1,726 | 45.7% | 0.3 |
Diabetes complications | ||||||||||
Microvascular | 1,521 | 16.5% | 1,109 | 24.6% | < 0.0001 | 769 | 20.4% | 766 | 20.3% | 0.2 |
Macrovascular | 1,530 | 16.6% | 1,349 | 30.0% | < 0.0001 | 879 | 23.3% | 906 | 24.0% | 1.7 |
Deyo charlson Comorbidity index | 1.4 | 1.1 | 1.8 | 1.5 | < 0.0001 | 1.6 | 1.3 | 1.6 | 1.3 | 0.1 |
Medication claims | 41.2 | 25.1 | 40.8 | 27.2 | 0.37 | 41.0 | 24.9 | 40.4 | 26.9 | 2.2 |
Medication classes | 9.9 | 4.4 | 9.9 | 4.7 | 0.60 | 9.7 | 4.2 | 9.8 | 4.6 | 1.5 |
Pre-index inpatient admissions | 815 | 8.9% | 952 | 21.2% | < 0.0001 | 530 | 14.0% | 543 | 14.4% | 1.0 |
Pre-index total healthcare costs | $9,749 | $12,251 | $14,536 | $31,763 | < 0.0001 | $11,194 | $15,747 | $11,245 | $18,254 | 0.3 |
Physician specialty | < 0.0001 | |||||||||
Primary care | 6,346 | 69.0% | 3,170 | 70.5% | 2,722 | 72.1% | 2,699 | 71.5% | 1.4 | |
Endocrinology | 1,168 | 12.7% | 210 | 4.7% | 204 | 5.4% | 198 | 5.2% | 0.7 | |
Other specialist | 1,016 | 11.0% | 680 | 15.1% | 524 | 13.9% | 529 | 14.0% | 0.4 | |
Missing/unknown | 667 | 7.3% | 439 | 9.8% | 324 | 8.6% | 348 | 9.2% | 2.2 | |
Treatment pre-Index | ||||||||||
Glucose lowering | 9,188 | 99.9% | 4,402 | 97.8% | < 0.0001 | 3,765 | 99.8% | 3,766 | 99.8% | 0.6 |
Biguanides (metformin) | 6,761 | 73.5% | 2,940 | 65.3% | < 0.0001 | 2,624 | 69.5% | 2,626 | 69.6% | 0.1 |
Sulfonylureas | 4,252 | 46.2% | 3,011 | 66.9% | < 0.0001 | 2,445 | 64.8% | 2,428 | 64.3% | 0.9 |
Meglitinides | 466 | 5.1% | 259 | 5.8% | 0.090 | 212 | 5.6% | 216 | 5.7% | 0.5 |
Thiazolidinediones | 4,688 | 51.0% | 2,382 | 52.9% | 0.030 | 2,085 | 55.2% | 2,082 | 55.2% | 0.2 |
α glucosidase inhibitors | 92 | 1.0% | 69 | 1.5% | 0.0065 | 44 | 1.2% | 53 | 1.4% | 2.1 |
Fixed dose therapies | 2,293 | 24.9% | 916 | 20.4% | < 0.0001 | 854 | 22.6% | 840 | 22.3% | 0.9 |
Cardiovascular | 8,493 | 92.3% | 4,111 | 91.4% | 0.049 | 3,470 | 91.9% | 3,463 | 91.8% | 0.7 |
Antihyperlipidemics | 6,526 | 71.0% | 3,074 | 68.3% | 0.0016 | 2,648 | 70.2% | 2,638 | 69.9% | 0.6 |
Antihypertensives | 7,693 | 83.6% | 3,814 | 84.8% | 0.091 | 3,183 | 84.3% | 3,187 | 84.4% | 0.3 |
Other | 3,164 | 34.4% | 1,308 | 29.1% | < 0.0001 | 1,089 | 28.9% | 1,106 | 29.3% | 1.0 |
Antidepressants | 2,890 | 31.4% | 1,138 | 25.3% | < 0.0001 | 952 | 25.2% | 978 | 25.9% | 1.6 |
Antiobesity | 82 | 0.9% | 10 | 0.2% | < 0.0001 | 9 | 0.2% | 10 | 0.3% | 0.5 |
Antiemetics/antinausea | 429 | 4.7% | 260 | 5.8% | 0.0051 | 202 | 5.4% | 203 | 5.4% | 0.1 |